Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Adefovir · Hepsera, GS-0393

Small molecule · Inhibitor of hepatitis B virus reverse transcriptase · developed by Gilead

Approved FDA, Sep 2002
1 Registered trials

What is Adefovir?

Adefovir is a nucleoside reverse transcriptase inhibitor, an analog of adenosine, that acts against hepatitis B virus, herpes virus and HIV.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Hepsera, GS-0393
Drug type
Small molecule
Targets
hepatitis B virus reverse transcriptase
Mechanism
Inhibitor of hepatitis B virus reverse transcriptase
Pathways
viral DNA replication
Therapy area
Infectious disease
Developer
Gilead
In trials of
AKBA
FDA status
Approved as Hepsera (September 20, 2002), NDA021449
UNII
6GQP90I798

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03801759 Phase 1 Drug Interaction Potentiation Completed AKBA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Drug Interaction Potentiation

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.